...
首页> 外文期刊>Journal of Medicinal Chemistry >Novel arylpyrazino(2,3-c)(1,2,6)thiadiazine 2,2-dioxides as platelet aggregation inhibitors. 2. Optimization by quantitative structure-activity relationships.
【24h】

Novel arylpyrazino(2,3-c)(1,2,6)thiadiazine 2,2-dioxides as platelet aggregation inhibitors. 2. Optimization by quantitative structure-activity relationships.

机译:新型芳基吡嗪并(2,3-c)(1,2,6)噻二嗪2,2-二氧化物作为血小板聚集抑制剂。 2.通过定量构效关系进行优化。

获取原文
获取原文并翻译 | 示例

摘要

In the previous paper (Part 1), we described the synthesis and antiplatelet activity of a series of phenyl- and heteroarylpyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxides. In this paper, we report the optimization of the platelet aggregation inhibitory activity by an iterative sequence of quantitative structure-activity relationship studies which encompassed synthesis and evaluation of the effects of structure variations at the 1-, 6-, and 7-positions of the heterocyclic system. A model has been established that correctly correlates antiplatelet activity in this series with the partial atomic charges calculated by a local density functional ab initio method. As a result of this study, the experimental platelet aggregation inhibitory activity of the lead compound was improved 300-fold.
机译:在上一篇文章(第1部分)中,我们描述了一系列苯基和杂芳基吡嗪并[2,3-c] [1,2,6]噻二嗪2,2-二氧化物的合成和抗血小板活性。在本文中,我们通过定量结构-活性关系研究的迭代序列报告了血小板凝集抑制活性的优化,该研究包括合成和评估在1、6和7位的结构变异的影响。杂环系统。已经建立了一个模型,该模型可以将该系列中的抗血小板活性与通过局部密度函数从头算法计算出的部分原子电荷正确相关。这项研究的结果是,铅化合物的实验性血小板聚集抑制活性提高了300倍。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号